JP2020500539A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500539A5
JP2020500539A5 JP2019530472A JP2019530472A JP2020500539A5 JP 2020500539 A5 JP2020500539 A5 JP 2020500539A5 JP 2019530472 A JP2019530472 A JP 2019530472A JP 2019530472 A JP2019530472 A JP 2019530472A JP 2020500539 A5 JP2020500539 A5 JP 2020500539A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
carbon
composition
lnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/065303 external-priority patent/WO2018107026A1/en
Publication of JP2020500539A publication Critical patent/JP2020500539A/ja
Publication of JP2020500539A5 publication Critical patent/JP2020500539A5/ja
Priority to JP2022101160A priority Critical patent/JP2022121531A/ja
Pending legal-status Critical Current

Links

JP2019530472A 2016-12-09 2017-12-08 標的特異的ヌクレアーゼの送達 Pending JP2020500539A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022101160A JP2022121531A (ja) 2016-12-09 2022-06-23 標的特異的ヌクレアーゼの送達

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662432042P 2016-12-09 2016-12-09
US62/432,042 2016-12-09
US201762458373P 2017-02-13 2017-02-13
US62/458,373 2017-02-13
US201762503470P 2017-05-09 2017-05-09
US62/503,470 2017-05-09
US201762559186P 2017-09-15 2017-09-15
US62/559,186 2017-09-15
PCT/US2017/065303 WO2018107026A1 (en) 2016-12-09 2017-12-08 Delivery of target specific nucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022101160A Division JP2022121531A (ja) 2016-12-09 2022-06-23 標的特異的ヌクレアーゼの送達

Publications (2)

Publication Number Publication Date
JP2020500539A JP2020500539A (ja) 2020-01-16
JP2020500539A5 true JP2020500539A5 (cg-RX-API-DMAC7.html) 2021-01-21

Family

ID=62492169

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530472A Pending JP2020500539A (ja) 2016-12-09 2017-12-08 標的特異的ヌクレアーゼの送達
JP2022101160A Pending JP2022121531A (ja) 2016-12-09 2022-06-23 標的特異的ヌクレアーゼの送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022101160A Pending JP2022121531A (ja) 2016-12-09 2022-06-23 標的特異的ヌクレアーゼの送達

Country Status (6)

Country Link
US (1) US20180185516A1 (cg-RX-API-DMAC7.html)
EP (1) EP3551169A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020500539A (cg-RX-API-DMAC7.html)
AU (1) AU2017374042C1 (cg-RX-API-DMAC7.html)
CA (1) CA3045122A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018107026A1 (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL264792B2 (en) 2016-08-24 2023-10-01 Sangamo Therapeutics Inc Engineered target-specific zinc-finger nucleases
WO2018039440A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
US11820728B2 (en) * 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
KR102712142B1 (ko) 2017-07-31 2024-10-07 리제너론 파마슈티칼스 인코포레이티드 Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
JP7355731B2 (ja) * 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
BR112020015488A2 (pt) 2018-02-08 2020-12-08 Sangamo Therapeutics, Inc. Nucleases alvo-específicas modificadas
JP7550648B2 (ja) 2018-03-19 2024-09-13 クリスパー セラピューティクス アーゲー 新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2020032184A1 (ja) 2018-08-10 2020-02-13 武田薬品工業株式会社 カチオン性脂質
JP7436990B2 (ja) * 2018-08-10 2024-02-22 国立大学法人京都大学 カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
EP4234570A3 (en) * 2018-09-18 2023-12-13 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
CA3116576A1 (en) * 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CA3121191A1 (en) * 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
JP7630904B2 (ja) * 2019-07-23 2025-02-18 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
GB2600859B (en) * 2019-08-14 2024-04-03 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids
CN114729376A (zh) 2019-09-23 2022-07-08 欧米茄治疗公司 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
AU2020355000A1 (en) 2019-09-23 2022-03-17 Sepia Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
WO2021183720A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
TWI899203B (zh) 2020-04-09 2025-10-01 大陸商蘇州艾博生物科技有限公司 脂質奈米粒子組成物
KR20230017783A (ko) * 2020-04-28 2023-02-06 인텔리아 테라퓨틱스, 인크. 시험관내 세포 전달 방법
KR20230040348A (ko) * 2020-07-15 2023-03-22 더 잭슨 래보라토리 Sars-cov-2 감염에 대한 인간화 마우스 모델
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
WO2022060871A1 (en) * 2020-09-15 2022-03-24 Verve Therapeutics, Inc. Lipid formulations for gene editing
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
WO2022236010A1 (en) * 2021-05-06 2022-11-10 The University Of North Carolina At Chapel Hill Use of chemical epigenetic modifiers to modulate gene expression from vectors
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
WO2023031855A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
AR127312A1 (es) * 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
WO2023069948A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
AU2022408167A1 (en) 2021-12-08 2024-06-06 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
WO2023242817A2 (en) 2022-06-18 2023-12-21 Glaxosmithkline Biologicals Sa Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
EP4716741A2 (en) 2023-05-23 2026-04-01 Flagship Labs 114, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2025010554A1 (en) * 2023-07-07 2025-01-16 Yoltech Therapeutics Co., Ltd. Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
TW202543583A (zh) 2024-03-01 2025-11-16 加拿大商阿奎特斯醫療公司 用於將治療劑包覆於脂質奈米顆粒中之材料及方法
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
TW202604548A (zh) * 2024-05-01 2026-02-01 加拿大商阿奎特斯醫療公司 使用脂質奈米顆粒進行肌內遞輸之方法
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026088119A1 (en) 2024-10-24 2026-04-30 Pfizer Inc. Lipidated tlr7/8 modulators as adjuvants and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758529B1 (en) * 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
ES2923757T3 (es) * 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CA2867323C (en) * 2012-03-27 2020-07-07 Sirna Therapeutics, Inc. Diether based biodegradable cationic lipids for sirna delivery
CA2892448A1 (en) * 2012-12-05 2014-06-12 Sangamo Biosciences, Inc. Methods and compositions for regulation of metabolic disorders
CA3229275A1 (en) * 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
CA2953341C (en) * 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016014794A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP4279084B1 (en) * 2015-10-28 2025-06-11 Vertex Pharmaceuticals Inc. Materials and methods for treatment of duchenne muscular dystrophy

Similar Documents

Publication Publication Date Title
US11534453B2 (en) RNAi therapy for hepatitis B virus infection
JP7766583B2 (ja) 強化された薬剤送達のための組成物及び方法
TWI811238B (zh) 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物
ES2765463T3 (es) Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne
US20200009268A1 (en) Expression constructs and systems for systemic and non-specific in vivo delivery of a nucleic acid to human cells and transient target cell-specific production of a therapeutic protein
US8309356B2 (en) Pseudocomplementary oligonucleotides for targeted gene therapy
CA3229270A1 (en) Rnai agents for hepatitis b virus infection
EP4069675A1 (en) Nanomaterials
EP3087988A2 (en) Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
BR112016020618B1 (pt) Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
US20220259597A1 (en) Oligonucleotide antagonists for rna guided genome editing
CN102459301A (zh) 亲脂性多聚核苷酸缀合物
JP2024515650A5 (cg-RX-API-DMAC7.html)
ES3022990T3 (en) Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
TW201907009A (zh) 用於治療b型肝炎之治療組成物及方法
JP2021526505A (ja) 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
KR20240118881A (ko) 항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
Ohto et al. Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles
JP2024545602A (ja) Hsd17b13関連二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
KR101685304B1 (ko) 간 조직 특이적 유전자 발현 억제인자 전달용 나노리포좀
US20220106608A1 (en) Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins
KR20160030099A (ko) 세포내 감염의 치료 방법
WO2026055547A1 (en) Dna compositions and related methods
US20210139870A1 (en) Anti-hbv combination therapies involving specific endonucleases
WO2019183005A1 (en) 2'f-ana-let7 mediated utrophin upregulation for dmd therapy